Abstract:Introduction: Immunogenicity refers to the ability of a substance, such as a therapeutic drug, to elicit an immune response. While beneficial in vaccine development, undesirable immunogenicity can compromise the safety and efficacy of therapeutic proteins by inducing anti-drug antibodies (ADAs). These ADAs can reduce drug bioavailability and alter pharmacokinetics, necessitating comprehensive immunogenicity risk assessments starting at early stages of drug development. Given the complexity of immunogenicity, an integrated approach is essential, as no single assay can universally recapitulate the immune response leading to the formation of anti-drug antibodies. Methods: To better understand the Dendritic Cell (DC) contribution to immunogenicity, we developed two flow cytometry-based assays: the DC internalization assay and the DC activation assay. Monocyte-derived dendritic cells (moDCs) were generated from peripheral blood mononuclear cells (PBMCs) and differentiated over a five-day period. The internalization assay measured the accumulation rate of therapeutic antibodies within moDCs, while the activation assay assessed the expression of DC activation markers such as CD40, CD80, CD86, CD83, and DC-SIGN (CD209). To characterize these two assays further, we used a set of marketed therapeutic antibodies. Results: The study highlights that moDCs differentiated for 5 days from freshly isolated monocytes were more prone to respond to external stimuli. The internalization assay has been shown to be highly sensitive to the molecule tested, allowing the use of only 4 donors to detect small but significant differences. We also demonstrated that therapeutic antibodies were efficiently taken up by moDCs, with a strong correlation with their peptide presentation on MHC-II. On the other hand, by monitoring DC activation through a limited set of activation markers including CD40, CD83, and DC-SIGN, the DC activation assay has the potential to compare a series of compounds. These two assays provide a more comprehensive understanding of DC function in the context of immunogenicity, highlighting the importance of both internalization and activation processes in ADA development. Discussion: The DC internalization and activation assays described here address key gaps in existing immunogenicity assessment methods by providing specific and reliable measures of DC function. The assays enhance our ability to pre-clinically evaluate the immunogenic potential of biotherapeutics, thereby improving their safety and efficacy. Future work should focus on further validating these assays and integrating them into a holistic immunogenicity risk assessment framework.

Improvement of human dendritic cell culture for immunotoxicological investigations

Effect of culture and maturation on human monocyte-derived dendritic cell surface markers, necrosis and antigen binding

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics

A comprehensive battery of flow cytometric immunoassays for the in vitro testing of chemical effects in human blood cells

Immunity Character of Dendritic Cells Derived from Two Blood

Dexmedetomidine Inhibits Maturation and Function of Human Cord Blood-Derived Dendritic Cells by Interfering with Synthesis and Secretion of Il-12 and Il-23

In vitro generation of mature dendritic cells from peripheral blood mononuclear cell by cocktail of cytokines

[Human Peripheral Blood Monocyte Derived Dendritic Cell Culture and Mature Regulation].

Evaluation of THP-1 and Jurkat Cell Lines Coculture for the In Vitro Assessment of the Effects of Immunosuppressive Substances

MONOCYTE-DERIVED DENDRITIC CELLS ISOLATION AND PHENOTYPIC CHARACTERIZATION

In vitro Production of Dendritic Cells as Cancer Immunotherapy: Highlights on Sample Source, Culture Period, Differentiation and Maturation Cytokines

Initial phase establishment of an in vitro method for developmental neurotoxicity test using Ki-67 in human neural progenitor cells

Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies

Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response.

Relative sensitivities of TDAR, cytokine production, and immunophenotyping assays in immunotoxicity assessment

A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors

Generation of Mature Dendritic Cells from Peripheral Blood Mononuclear Cells by Calcium Ionophore and Poly (I:C) in Vitro

Induction of human peripheral blood monocyte-derived dendritic cells in vitro

A high-throughput approach to identify specific neurotoxicants/ developmental toxicants in human neuronal cell function assays

Improvement of bone marrow mononuclear cells cryopreservation methods to increase the efficiency of dendritic cell production

Effect of different culture mediums on the development of monocyte-derived dendritic cells]